Timing note: BD scheduled its fiscal third-quarter earnings call for 8:00 a.m. ET on Thursday, August 6, 2026—today, rather than tomorrow. The quarter ended June 30, 2026. This preview uses information available through the August 5 market close.
BD enters the quarter with improving execution but a meaningfully higher expectations bar. The shares closed August 5 at $170.69, up roughly 18% since May 6, the day before its last earnings report. At approximately 13.5 times the midpoint of fiscal 2026 adjusted EPS guidance, valuation remains moderate, but the recent rally means another merely “in-line” report may not be sufficient.
The central question is no longer whether the newly streamlined BD can cut costs. Management has established credibility around productivity, margin protection and capital returns. Investors now need evidence that the company can produce better and more durable underlying revenue growth, particularly as the Alaris replacement-cycle headwind gets worse in fiscal 2027.
| Metric | Current expectation / prior guidance |
|---|---|
| Fiscal 3Q26 adjusted EPS | Approximately $3.14 |
| FX-neutral revenue growth | Approximately 2.6% |
| FY26 FX-neutral revenue guidance | Low single digits |
| FY26 adjusted EPS guidance | $12.52–$12.72 |
| FY26 adjusted operating-margin target | Approximately 25% |
| Latest reported net leverage | Approximately 2.9x |
BD reported first-half adjusted EPS of $5.38. If third-quarter EPS lands near $3.14, the company would need approximately $4.00–$4.20 in fiscal fourth-quarter EPS to reach its full-year range. Seasonality and buyback benefits should help, but the math makes the quality of the outlook at least as important as the third-quarter result.
Last quarter, management said more than 90% of the portfolio was producing approximately mid-single-digit growth. That strength was masked by three concentrated pressures—Alaris, vaccines and China—which together represented less than 10% of revenue.
A constructive report would show that this divergence remains intact:
A headline FX-neutral growth rate near 2.5% can be acceptable if the underlying mix is healthy. The more concerning outcome would be softer growth across businesses previously described as strong.
Connected Care is likely to generate the most debate.
The Alaris business faces difficult capital-equipment comparisons as BD finishes its remediation and replacement cycle. Management previously quantified the Alaris drag at roughly 100 basis points of company growth in fiscal 2026, rising to approximately 200 basis points in fiscal 2027.
At the same time, operating indicators have been encouraging:
Investors should separate weak reported Alaris capital revenue from the health of the franchise. Continued share gains, consumables pull-through and Pyxis Pro adoption would support the view that the current decline is a temporary comparison issue rather than competitive deterioration.
Advanced Patient Monitoring is another key indicator. It grew approximately 12% last quarter and was tracking ahead of the original acquisition model. A sharp deceleration would weaken one of the principal growth pillars of “New BD.”
BioPharma Systems declined 1.8% on an FX-neutral basis last quarter because lower vaccine-product demand more than offset double-digit biologics growth.
The bull case rests on a favorable mix transition:
Investors should listen for whether vaccine comparisons are beginning to ease and whether GLP-1 and broader biologics demand can return the segment to growth. The July decision to have BioPharma Systems report directly to CEO Tom Polen reinforces its strategic importance.
Fiscal Q2 adjusted operating margin was 24.2%, ahead of management’s expectations despite an approximately 160-basis-point tariff burden. BD Excellence delivered around 8% productivity, and the company had completed $150 million of the run-rate benefit under a $200 million cost-reduction program.
For the third quarter, the important questions are:
Management previously said resins and molded plastics account for about 5% of cost of goods sold and that roughly half of North American resin purchases were hedged. Those protections help fiscal 2026, but pricing and further productivity may be needed next year.
Fiscal Q2 FX-neutral growth was 1.7%, with U.S. share gains in vascular access and Vacutainer offset by China.
The May ChloraPrep ship hold should not be a major third-quarter financial issue: BD resumed U.S. ChloraPrep shipments on May 29 after acceptable additional testing and reported no patient-safety signals. Investors should nevertheless seek an update on the El Paso FDA warning letter, the status of PurPrep and whether the additional testing has created incremental cost or supply constraints.
What would be positive: better international performance, continued U.S. share gains and no residual ChloraPrep disruption.
Fiscal Q2 FX-neutral growth was 3.2%, led by 12% growth in Advanced Patient Monitoring. Medication Management Solutions grew only modestly because of the Alaris capital comparison.
What would be positive: continued double-digit APM growth, Alaris share gains, healthy consumables pull-through and competitive Pyxis Pro wins.
Fiscal Q2 FX-neutral revenue declined 1.8%.
What would be positive: improving vaccine comparisons, continued double-digit biologics growth and evidence that recent GLP-1 wins are moving toward commercial production.
This was the strongest broad segment last quarter, growing 5.3% FX-neutral. PureWick, Advanced Tissue Regeneration, infection prevention, peripheral vascular disease and oncology all contributed.
What would be positive: another mid-single-digit-or-better quarter with broad contribution rather than reliance on a single product.
A fiscal 2026 guidance increase is possible if third-quarter margins and EPS outperform, but maintaining the existing range would not necessarily be disappointing. Management may prefer to retain room for tariffs, China and vaccine uncertainty.
The more consequential discussion will concern fiscal 2027:
Investors should distinguish between the reported fiscal 2027 growth rate and the underlying growth of the portfolio excluding Alaris. A low headline number accompanied by healthy core growth and continued share gains could still support the longer-term thesis.
BD generated $1.1 billion of first-half free cash flow, repurchased approximately $2.25 billion of shares through the first half—including a $2 billion accelerated repurchase—and retired $2.1 billion of debt in fiscal Q2.
Points to watch:
The buyback should provide an important fiscal 2026–27 EPS tailwind. However, investors should still prioritize organic operating progress over financially engineered per-share growth.
Mike Garrison, president of Medical Essentials and BioPharma Systems, is scheduled to retire effective October 2. BD is searching for a new Medical Essentials president, while BioPharma Systems will report directly to Polen.
The change is not an immediate earnings issue, but investors may ask whether:
Given the recent share-price appreciation, this outcome could produce a muted or mixed reaction.
BD’s third-quarter report is primarily a test of revenue quality and forward visibility, not cost-cutting ability. The company has already shown that BD Excellence, portfolio simplification and repurchases can support earnings. To sustain the stock’s rerating, it now needs to demonstrate that its high-growth platforms are scaling quickly enough to overcome Alaris, vaccines and China—and that fiscal 2027 represents the peak of the transition rather than another year of delayed acceleration.
The most important indicators will be core portfolio growth, Alaris share and consumables trends, Advanced Patient Monitoring growth, biologics momentum, operating-margin durability and the implied fiscal fourth-quarter earnings bridge.
Research basis: BD’s fiscal 2Q26 earnings release and call, latest 10-Q and 8-K disclosures, subsequent company announcements, market-news consensus data, and stock prices through August 5, 2026.